Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise

Hyundai Pharm112 enrolled

Overview

A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 2 Study to Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

112

Conditions

Type 2 Diabetes Mellitus

Interventions

HD-6277DRUG

HD-6277 100mg

HD-6277DRUG

HD-6277 50mg

PlaceboDRUG

Placebo

Eligibility

Sex: ALLMin age: 19 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of T2DM with HbA1c between 7.0% and 10.0% (inclusive) while on diet and exercise alone for at least 6 weeks prior to screening. Exclusion Criteria: * Type 1 diabetes or another immune-mediated diabetes syndrome

Locations (1)

Included Severance Hospital, 10 sites

Seoul, South Korea

Outcomes

Primary Outcomes

Change in HbA1c(%) at weeks 12 from baseline

Time frame: at weeks 12 from baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.